Bartter's syndrome: effect of indomethacin on prostaglandins, urinary kallikrein, renin-angiotensin-aldosterone system, and the response to angiotensin II antagonist.
D015059:1-Sarcosine-8-Isoleucine Angiotensin II / Q000627:therapeutic use; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000616:Aminoglutethimide / Q000627:therapeutic use; D000804:Angiotensin II / Q000097:blood; D001241:Aspirin / Q000627:therapeutic use; D001477:Bartter Syndrome / Q000188:drug therapy / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D004039:Diet, Sodium-Restricted; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000378:metabolism*; D007213:Indomethacin / Q000627:therapeutic use*; D007610:Kallikreins / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011458:Prostaglandins E / Q000097:blood* / Q000652:urine; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use
D011458:Prostaglandins E; D000616:Aminoglutethimide; D000804:Angiotensin II; D013148:Spironolactone; D000450:Aldosterone; D015059:1-Sarcosine-8-Isoleucine Angiotensin II; D007610:Kallikreins; D012083:Renin; D001241:Aspirin; D007213:Indomethacin